On 17 January 2007 Pfizer Ltd officially notified the Committee for Medicinal Products for Veterinary Use (CVMP) that it wishes to withdraw its application for a new indication for the treatment of bovine interdigital necrobacillosis associated with Bacteroides melaninogenicus, Bacteroides nodosus and Fusobacterium necrophorum.
Questions and answers on the withdrawal of the application to change the marketing authorisation application for Draxxin
Reference Number: EMEA/CVMP/58270/2007
English (EN) (80.95 KB - PDF)
First published: Last updated: